Presentation of NEX-22 phase I data: A once-monthly GLP-1 injection receives positive response at the 85th ADA Scientific Sessions in Chicago
Nanexa announces that the poster titled "A Single Ascending Dose Study of a Once-monthly Liraglutide Formulation in Participants with Type 2 Diabetes" was presented by the renowned diabetes researcher Dr. Hans de Vries, on Sunday, June 22, at the American Diabetes Association’s 85th Scientific Sessions. The poster, which presented all data, including the 30 mg NEX-22 dose cohort, was very well received, and there has been significant interest in the first published clinical data with a once-montly long-acting injection of a GLP-1 drug. A 30 mg dose of NEX-22 shows exposure for up to 36 days without significant gastrointestinal side effects. This is not only highly positive for NEX-22, but all other potential GLP-1/GIP formulations which make use of PharmaShell.
The ADA’s Scientific Sessions is the world’s largest diabetes meeting, convening more than 11,000 attendees from around the globe to share cutting-edge scientific discoveries and advancements in diabetes care and innovation.
"We are very pleased with the attention we have received and the new contacts we have made during this important event. We see a great need for drugs that improve and simplify the treatment of both Type 2 diabetes and obesity," says David Westberg, CEO of Nanexa. "We are happy to being part of the development of important pharmaceuticals that can enhance the quality of life for many people."
The poster is already digitally available to all ADA members and conference attendees, and in August, it will also be publicly available on ADA’s official portal. The poster is also available on Nanexa’s website.
Authors of the poster: Dr. Hans de Vries, Dr. Tim Heise, Dr. Grit Andersen, Kristine Bäck, Erik Westrin, Maria Nehlin, Marie Gårdmark and Dr. Owe Luhr.